Comparative Pharmacology
Head-to-head clinical analysis: OGEN 5 versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 5 versus STILPHOSTROL.
OGEN 5 vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
0.625 mg orally once daily, adjusted based on response.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen
Estrogen